Practice Expertise
- Corporate & Commercial
- Mergers & Acquisitions
- Industry & Commerce
- Healthcare & Life Sciences
Areas of Practice
- Corporate & Commercial
- Healthcare & Life Sciences
- Industry & Commerce
- Mergers & Acquisitions
- Corporate / M&A
- Start-ups & Venture Capital View More
Profile
Karina Tschon works as an Attorney at Law at Walder Wyss. She advises clients on matters of commercial and corporate law.
Born in 1990, Karina Tschon studied at the University of Basel (BLaw 2014, MLaw 2016). Prior to joining Walder Wyss as an Attorney at Law, she worked as a trainee lawyer at the Civil District Court Basel-Landschaft East, the Criminal Court of Basel-Stadt, in a law firm in Basel and in the legal department of a pharmaceutical company in Basel. Karina Tschon was admitted to the bar in 2019 in the canton of Basel-Stadt.
Karina Tschon's professional languages are German and English.
Born in 1990, Karina Tschon studied at the University of Basel (BLaw 2014, MLaw 2016). Prior to joining Walder Wyss as an Attorney at Law, she worked as a trainee lawyer at the Civil District Court Basel-Landschaft East, the Criminal Court of Basel-Stadt, in a law firm in Basel and in the legal department of a pharmaceutical company in Basel. Karina Tschon was admitted to the bar in 2019 in the canton of Basel-Stadt.
Karina Tschon's professional languages are German and English.
Areas of Practice
- Corporate & Commercial
- Healthcare & Life Sciences
- Industry & Commerce
- Mergers & Acquisitions
- Corporate / M&A
- Start-ups & Venture Capital
Professional Career
Significant Accomplishments
Promotions at Walder Wyss
Nouscom Raises €67.5m ($72m) in Oversubscribed Series C Financing Round
LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections
Pierre Fabre Laboratories acquires Vertical Bio AG
Alentis Therapeutics Closes USD 105m Series C Funding
Investorengruppe erwirbt iPet.ch GmbH
BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital
Versant Ventures launches Vector BioPharma with USD 30m Series A
BioVersys announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR therapies
ImmunOs Therapeutics Raises USD 74 Million Series B Financing Round
Astorg acquires CordenPharma from ICIG
Engimmune Therapeutics raises CHF 15.5m in Seed Financing
Versant Ventures launches Cimeio Therapeutics with USD 50m Series A
kooky sichert sich Finanzierung über EUR 6 Millionen
Memo Therapeutics Closes Series B Financing at CHF 37m Following Oversubscribed CHF 23m Extension
Alloy Therapeutics acquires deepCDR Biologics
GlycoEra CHF 45m Series A Financing
Perconex Holding GmbH kauft Flex Suisse AG
Polyphor and EnBiotix sign merger agreement and agreement on sale of Murapavadin
Alentis Therapeutics erhält USD 67 Mio. im Rahmen einer Serie-B-Finanzierung
proLogistik Holding GmbH erwirbt XELOG AG
Calibre Scientific, Inc. acquires HUBERLAB.AG
Boehringer Ingelheim kauft NBE-Therapeutics für EUR 1,18 Milliarden
Noema Pharma Serie A-Finanzierungsrunde über CHF 54 Mio.
Synendos Therapeutics CHF 20m Series A Financing
VectivBio USD 110m Crossover Financing
Monte Rosa Therapeutics Serie B-Finanzierungsrunde über USD 96 Mio.
BioVersys Serie B-Finanzierungsrunde über CHF 19 Mio.
Versant Ventures lanciert Matterhorn Biosciences
Versant Ventures bringt Bright Peak Therapeutics auf den Markt
Walder Wyss berät BC Platforms im Hinblick auf die Series C Finanzierung über USD 15 Millionen sowie eine Partnerschaft mit IQVIA zum Ausbau der Datenanalytik im Bereich Genomik
Promotions at Walder Wyss
Nouscom Raises €67.5m ($72m) in Oversubscribed Series C Financing Round
LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections
Pierre Fabre Laboratories acquires Vertical Bio AG
Alentis Therapeutics Closes USD 105m Series C Funding
Investorengruppe erwirbt iPet.ch GmbH
BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital
Versant Ventures launches Vector BioPharma with USD 30m Series A
BioVersys announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR therapies
ImmunOs Therapeutics Raises USD 74 Million Series B Financing Round
Astorg acquires CordenPharma from ICIG
Engimmune Therapeutics raises CHF 15.5m in Seed Financing
Versant Ventures launches Cimeio Therapeutics with USD 50m Series A
kooky sichert sich Finanzierung über EUR 6 Millionen
Memo Therapeutics Closes Series B Financing at CHF 37m Following Oversubscribed CHF 23m Extension
Alloy Therapeutics acquires deepCDR Biologics
GlycoEra CHF 45m Series A Financing
Perconex Holding GmbH kauft Flex Suisse AG
Polyphor and EnBiotix sign merger agreement and agreement on sale of Murapavadin
Alentis Therapeutics erhält USD 67 Mio. im Rahmen einer Serie-B-Finanzierung
proLogistik Holding GmbH erwirbt XELOG AG
Calibre Scientific, Inc. acquires HUBERLAB.AG
Boehringer Ingelheim kauft NBE-Therapeutics für EUR 1,18 Milliarden
Noema Pharma Serie A-Finanzierungsrunde über CHF 54 Mio.
Synendos Therapeutics CHF 20m Series A Financing
VectivBio USD 110m Crossover Financing
Monte Rosa Therapeutics Serie B-Finanzierungsrunde über USD 96 Mio.
BioVersys Serie B-Finanzierungsrunde über CHF 19 Mio.
Versant Ventures lanciert Matterhorn Biosciences
Versant Ventures bringt Bright Peak Therapeutics auf den Markt
Walder Wyss berät BC Platforms im Hinblick auf die Series C Finanzierung über USD 15 Millionen sowie eine Partnerschaft mit IQVIA zum Ausbau der Datenanalytik im Bereich Genomik
